Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd. (Atom Bioscience)
Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd. (Atom Bioscience) was founded in 2012. The executive team is primarily from the United States and has extensive experience in the pharmaceutical industry. Atom Bioscience is a research-based pharmaceutical company engaged in new drug discovery and development on treatments for metabolic diseases and cancers. Among the several pipelines that Atom Bioscience develops, ABP-671, a novel compound for gout treatment has completed Phase I clinical trials in the United States and is undergoing Phase II clinical trials in Australia. ABP-671 may be a potent drug for treatment of gout and other hyperuricemia related diseases.
Novel compounds ABP-6016 and ABP-431 are currently under pre-clinical development for NASH and gastric cancer, respectively. Atom Bioscience expects both ABP-6016 and ABP-431 to enter clinical trials in 2022.